SS-31 (also called Elamipretide or Bendavia) is a synthetic tetrapeptide that targets the inner mitochondrial membrane to stabilize energy production and reduce cellular damage linked to mitochondrial dysfunction.
What it does
SS-31 is a four-amino-acid peptide with an alternating aromatic-cationic structure that causes it to concentrate more than 1,000-fold inside mitochondria — the organelles responsible for producing cellular energy Cheryl 2025. Once there, it binds cardiolipin, a specialized phospholipid found almost exclusively on the inner mitochondrial membrane. Cardiolipin acts as structural scaffolding for the electron transport chain (ETC) — the series of protein complexes that convert nutrients into ATP, the cell's energy currency. When cardiolipin is intact, ETC complexes are organized efficiently; when it degrades, the chain leaks electrons Wayne 2022.
Electron leak generates reactive oxygen species (ROS) — unstable molecules that damage proteins, fats, and DNA. Most conventional antioxidants (vitamins C and E, glutathione) work by mopping up ROS after they've already formed. SS-31 works upstream: by stabilizing the cardiolipin-cytochrome c interaction, it keeps the ETC running cleanly so fewer ROS are produced in the first place Cheryl 2025. This is a mechanistically distinct approach, not just a more potent version of a standard antioxidant.
Aging accelerates cardiolipin oxidation, which disrupts ETC organization, which increases ROS, which damages more cardiolipin — a reinforcing cycle. SS-31 interrupts this loop directly at the membrane Nadiya 2025. The same mechanism has shown relevance in heart disease, kidney injury, neurodegeneration, and rare mitochondrial disorders S 2026 Neil 2025 Baylen 2025.
What the evidence shows
Heart failure and cardiac mitochondrial dysfunction Strong animal evidence; limited but promising human trial data
In mouse models of Barth syndrome — a rare genetic disorder caused by defective cardiolipin remodeling — SS-31 restored normal mitochondrial morphology, improved mitophagy (the cell's process for clearing damaged mitochondria), and reduced cardiac dysfunction Silvia 2024 Silvia 2022. A separate rodent study found SS-31 activated mitoGPX4 and reduced ferroptosis (a form of iron-dependent cell death) in diabetic cardiomyopathy models Lie 2024. In humans, an open-label extension of the MMPOWER trial in primary mitochondrial myopathy patients showed tolerability at 40 mg/day subcutaneous dosing NCT02805790. A dedicated Barth syndrome trial is completed but full results remain limited in the literature NCT03098797 Neil 2025.
Acute kidney injury (AKI) Strong rodent and mechanistic evidence; early-stage human data
Mitochondrial dysfunction is a central driver of AKI, making SS-31 a logical candidate. Preclinical models show it preserves tubular cell function under ischemic and toxic stress by maintaining ETC efficiency and reducing ROS-mediated damage S 2026. Human trials in cardiac surgery-associated AKI (where the HARP trial was conducted) showed safety signals but mixed efficacy outcomes — the peptide appears more effective when administered before injury than after. No large randomized trial in AKI has yet reported definitive efficacy data.
Neurodegenerative and spinal cord injury Early-stage rodent and in vitro data; no human trials yet
SS-31 showed neuroprotective effects in both cell culture and rodent spinal cord injury models, reducing neuronal death and preserving mitochondrial membrane potential after injury Baylen 2025. In Friedreich's ataxia models, a related mechanism involving mitochondrial fragmentation was partially reversed by targeting Drp1-dependent pathways, consistent with SS-31's broader mitochondrial stabilization approach Joseph 2021. These findings are mechanistically compelling but have not yet advanced to human trials.
Age-related macular degeneration (AMD) with geographic atrophy Phase 2 human trial completed; results limited
The ReCLAIM-2 study enrolled patients with non-central geographic atrophy (a late form of AMD) to evaluate whether elamipretide could slow retinal degeneration — a tissue with extremely high mitochondrial density and ROS burden NCT03891875. The trial completed enrollment, but published efficacy data are not yet widely available. AMD is a biologically plausible target given that retinal pigment epithelial cells are among the most metabolically demanding in the body.
Barth syndrome (rare mitochondrial disease) Small human trials; supportive animal and case data
Barth syndrome is caused by mutations in tafazzin, an enzyme required for cardiolipin remodeling — making SS-31 a direct mechanistic fit. Animal studies using tafazzin knockdown mice showed SS-31 improved cardiac and mitochondrial function Silvia 2022 Silvia 2024. A dedicated pediatric trial evaluated safety and tolerability NCT03098797, and recent case reports describe functional improvement in individual patients on elamipretide Neil 2025. The evidence base here is small but more targeted than most indications.
How it's used
In clinical trials, the standard dose has been 40 mg/day administered subcutaneously (injected under the skin), typically as a single daily dose NCT02805790. Some protocols have used 20 mg/day as a lower starting dose, and 60 mg/day has appeared in higher-end research contexts. The peptide's half-life is roughly 3–6 hours, though mitochondrial accumulation may extend its functional effect beyond plasma levels. Morning dosing is common in self-reported protocols but timing appears flexible given the mechanism. SS-31 is not orally bioavailable in meaningful amounts and is formulated for subcutaneous or intravenous injection in clinical settings Cheryl 2025 Wayne 2022.
Side effects and safety
Across published trials and case reports, SS-31 has shown a relatively clean safety profile at doses up to 40 mg/day. The most commonly reported issues are injection site reactions and mild headache Cheryl 2025 Neil 2025. Moderate effects including dizziness and nausea have been noted in some participants. No severe adverse events have been directly attributed to the peptide in published data. Caution is warranted in severe renal impairment given that renal clearance contributes to elimination. Use during pregnancy is contraindicated due to absence of safety data. Long-term safety data beyond trial durations (typically weeks to months) are not available, and effects of chronic dosing in healthy individuals are unknown.
Bottom line
SS-31 has a well-characterized mitochondrial mechanism and meaningful preclinical evidence across multiple disease contexts, with early human trial data supporting tolerability. The strongest human evidence is in rare mitochondrial diseases like Barth syndrome; broader indications like heart failure and AKI have biological rationale but await larger trials. It's a legitimate research-stage compound — not fringe science — but anyone using it outside a clinical trial is ahead of the evidence on efficacy.